


CERTIFICATE OF MAILING

I hereby certify that this paper and every paper referred to therein as being enclosed is being deposited with the U.S. Postal Service as first class mail, postage prepaid, in an envelope addressed to: Commissioner of Patents & Trademarks, Washington, DC 20231

on September 29, 1999 (Date of Deposit)

9/29/99 A. DiCullo
Date Name



RECEIVED

OCT 05 1999

TECH CENTER 1600/2900

0342/1D888US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Charles E. ROGLER

Serial No.: 09/344,189

Group Art Unit: 1632

Filed: 06/24/99

Examiner:

For: CHRONIC HEPATITIS VIRUS INFECTION AND CLONAL HAPATOCELLULAR
CARCINOMA IN MOUSE REPOPULATED LIVERS

September 28, 1999

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the disclosure duty under 37 CFR §§ 1.56 and 1.97, the documents listed below and on the accompanying PTO-1449 are hereby cited as prior art.¹ All

¹ If a listed document is not in the English language and an English translation is readily available, such translation is also enclosed and attached to the copy of the document. If a translation is not attached, it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then the English equivalent patent is also listed on the enclosed form along with the corresponding foreign language patent and a connecting arrow indicates the relationship between them. If no such English language equivalent is cited, then none is known to the undersigned.

of the references were provided in an Information Disclosure Statement filed in the parent application (Ser. No. 09/156,892 filed 09/18/98) on December 21, 1998 except reference No. 19 as listed below and on the attached PTO Form 1449. Therefore only this document No. 19 is enclosed herewith. These documents contain information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent:

1. Chisari, F.V. *et al.* (1995) *Annu. Rev. Immunol.* 13:29-60
2. Chisari, F.V. (1996) *Curr Topics Microbiol Immunol* 206:150-173
3. Guidotti, L.G. *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:3764-3768
4. Guidotti, L. G. *et al.* (1996) *Immunity* 4:25-36
5. Gupta, S. *et al.* (1996) *Prog Liv Dis* 14:199-222
6. Sandgren, E.P. *et al.* (1991) *Cell* 66:245-256
7. Rhim, J.A. *et al.* (1994) *Science* 263:1149-1152
8. Rhim, J.A., *et al.* (1995) *Proc. Natl. Acad. Sci. USA* 92:4942-4946
9. Roggendorf, M. *et al.* (1995) *Intervirology* 38:100-112
10. Korba, B.E. *et al.* (1989). *J Virol* 63:1360-70
11. Tennant, B.C. *et al.* (1994) in *The Liver. Biology and Pathobiology*, eds. Arias, I.M., *et al.* (Raven Press, New York) pp 1455-1469
12. Shinkai, Y. *et al.* (1992) *Cell* 68:855-867
13. Overturf, K. *et al.* (1996) *Nature Genetics* 12:266-273
14. Grompe, M. *et al.* (1993) *Genes and Development* 7:2298-2307
15. Overturf, K. *et al.* (1997) *Am. J. Path.* 151:1273-1280
16. Marie-Jeanne, T. *et al.* (1997) *Hepatology* 25:884-888
17. Petersen, J. *et al.* (Sept. 1997) Abstract No. 041, Molecular Biology of Hepatitis B Viruses, Institut Pasteur
18. Petersen, J. *et al.* (1998) *Proc. Natl. Acad. Sci. USA* 95:310-315
19. Petersen, J. *et al.* (1997) *Hepatology* 26(4), pt. 2, 225A, Abstract # 387


In accordance with MPEP Sections 609 and 707.05(b) it is requested that each document cited (including any cited in applicants' specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449, so that it will appear on the face of the patent issuing on the present application, even if the Examiner does not

consider it sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with.

The present Disclosure Statement is also being submitted in compliance with 37 CFR § 1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents are relevant or effective as prior art, or that they represent the results of a complete search, and it is anticipated that the Examiner in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR §§ 1.104(a) and 1.106(b), and in the course of such search will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,



Anne E. Zitron, Ph.D.
Reg. No. 41,391
Agent for Applicant(s)

DARBY & DARBY
805 Third Avenue
New York, New York 10022
(212) 527-7700
::ODMA\WORLD\OX\M:\0342\1D888\KRJ2034.WPD